AstraZeneca bags CHMP’s recommendation for Trixeo Aerosphere & Forxiga
Category: #health  By Pankaj Singh  Date: 2020-10-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca bags CHMP’s recommendation for Trixeo Aerosphere & Forxiga

 

  • AstraZeneca is likely to get approval from the EU after receiving a recommendation from CHMP
  • AstraZeneca is also cleared to resume its COVID-19 vaccine trial in various countries

British pharmaceutical firm, AstraZeneca has recently announced that it has bagged recommendations from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for approval of two drugs, namely Trixeo Aerosphere and Forxiga, in the European Union.

According to reliable sources, Forxiga is useful for treating symptomatic chronic heart failure in adults without or with type-2 diabetes. The drug was approved under the brand name Farxiga in the United States in May 2020. As for Trixeo Aerosphere, it helps in maintenance treatment among adult patients with severe to moderate chronic obstructive pulmonary disease (COPD). This drug is sold under the brand name Breztri Aerosphere in Japan, China, and the US.

Reportedly, the European committee (CHMP) recommended Trixeo Aerosphere after analyzing data from the KRONOS Phase III study, where they found tolerability and safety to be consistent. While with Forxiga, the committee stated that the medicine is used by adults for the symptomatic chronic HFrEF treatment. It assured the regulators by saying that Forxiga is cleared by the US FDA and is approved in various other countries.

AstraZeneca, along with Oxford University, is also in the race to develop a vaccine for COVID-19. The World Health Organisation (WHO) has called its candidate a frontrunner in the development process. However, the pharmaceutical firm had to halt its clinical trial after their volunteers developed unspecified illnesses. But, after some investigation, the company was given a green signal to resume its clinical trials.

The FDA has also cleared AstraZeneca to continue its COVID-19 vaccine trial in the United States after completing a thorough review of the matter. Sources cite that the trial could resume later this week.

Source Credit: https://www.republicworld.com/world-news/rest-of-the-world-news/astrazeneca-gets-approval-recommendation-for-two-drugs-from-eu-agency.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Supemtek® influenza vaccine gains approval in European Union
Supemtek® influenza vaccine gains approval in European Union
By Pankaj Singh

The European Commission has recently approved the authorization for commercialization of Supemtek®, a quadrivalent recombinant technology-based influenza vaccine, designed for preventing influenza among ...

Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination
Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination
By Pankaj Singh

Zymeworks Inc., a clinical-stage biopharmaceutical company involved in developing multifunctional biotherapeutics has recently entered into a clinical collaboration with ALX Oncology Holdings Inc., a clinical-stage imm...

DW Healthcare Partners invests in virtual care provider CareXM
DW Healthcare Partners invests in virtual care provider CareXM
By Pankaj Singh

Healthcare focused private equity firm, DW Healthcare Partners, has reportedly shared plans to partner with virtual care and patient engagement solutions provider, CareXM. The deal represents one of the three investmen...